Global Kratom Coalition Applauds DEA Order on Synthetic Alkaloids, Calls It a Win for Natural Kratom

Why it matters

The kratom industry's trade alliance is actively distinguishing natural botanical kratom from the synthetic compounds now under federal Schedule I control—a distinction that could determine whether mainstream kratom products remain legal during the current regulatory wave.

The big picture

The Global Kratom Coalition (GKC) represents consumers, researchers, and industry leaders who favor science-based regulation of natural kratom over blanket prohibition. The GKC has been tracking the DEA's rulemaking since the July 2026 notice of intent and is now positioning itself ahead of the expected follow-on action targeting concentrated 7-OH. The coalition is also directing state and local policymakers to follow the DEA's lead in drawing a chemical line between synthesized compounds and plant-derived products.

Key findings

• The DEA order published August 26 covers only MGPI, MGM-15, and MGM-16—none of which occur naturally in the kratom plant
• The order does not schedule unaltered natural kratom leaf, powders, capsules, teas, or other leaf products without additional chemical processing
• DEA's own order describes traditional kratom use as 'chewing raw leaves or steeping leaves into water decoctions and teas'
• The GKC expects DEA to finalize a companion 7-OH action after the September 10 comment period closes
• GKC urges state and local policymakers to follow DEA's lead and distinguish natural kratom from synthetic derivatives
• The order remains in effect through August 26, 2028

What they say

"DEA is demonstrating bold, science-driven leadership by taking aim at these rogue synthetic opioid products," said Matthew Lowe, GKC Executive Director. "Health and Human Services Secretary Robert F. Kennedy Jr. and DEA Administrator Terrance Cole deserve credit for finalizing a rule that will bring an end to these dangerous products. This is a win for public health."

Bottom line

The GKC framing is clear: the DEA targeted lab-made opioids, not kratom, and the industry wants policymakers at every level to honor that distinction.